Detalhe da pesquisa
1.
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.
Int J Mol Sci
; 23(10)2022 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35628443
2.
Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
J Clin Gastroenterol
; 50(2): 147-51, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25811118
3.
Knowledge, Perceptions, and Perspectives of Medical Students Regarding the Use of Antibiotics and Antibiotic Resistance: A Qualitative Research in Galicia, Spain.
Antibiotics (Basel)
; 12(3)2023 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36978424
4.
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.
Biomed Pharmacother
; 161: 114535, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36931025
5.
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Front Pharmacol
; 13: 827033, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35185578
6.
A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Liver Transpl
; 15(11): 1542-52, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19877219
7.
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Biochem Pharmacol
; 170: 113677, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647926